Get the Stockscreener App
155.51
0.78%
-1.23
Biogen Inc stock is traded at $155.51, with a volume of 1.42M.
It is down -0.78% in the last 24 hours and up +2.17% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$156.74
Open:
$156.7
24h Volume:
1.42M
Relative Volume:
0.87
Market Cap:
$22.80B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
14.88
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
+0.80%
1M Performance:
+2.17%
6M Performance:
+32.68%
1Y Performance:
-10.59%
1-Day Range:
$151.83
$156.70
1-Week Range:
$148.51
$157.80
52-Week Range:
$110.03
$175.86
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
155.51 | 22.99B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
924.37 | 839.03B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.57 | 450.47B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
219.16 | 387.13B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.35 | 242.86B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
86.28 | 212.91B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Is Biogen Worth a Fresh Look After Major Drug Approvals in 2025? - simplywall.st
Biogen Inc.’s volatility index tracking explained2025 Biggest Moves & Stock Portfolio Risk Control - newser.com
Stifel Upgrades Biogen (BIIB) - Nasdaq
Biogen Shares Rise After Stifel Upgrade - MarketScreener
Biogen (BIIB) Valuation in Focus After Q3 Earnings Growth and Share Buyback Update - simplywall.st
Why Biogen Inc. (IDP) stock stays on top picksWeekly Volume Report & AI Driven Price Predictions - newser.com
December 26th Options Now Available For Biogen (BIIB) - Nasdaq
Historical volatility pattern of Biogen Inc. visualized2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - MSN
Stifel Upgrades Biogen (BIIB) to 'Buy', Raises Price Target to $202 | BIIB Stock News - GuruFocus
Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift - Yahoo! Finance UK
Here Are Thursday's Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - 24/7 Wall St.
Will Biogen Inc. stock benefit from upcoming earnings reportsRisk Management & Technical Pattern Based Signals - fcp.pa.gov.br
Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift By Investing.com - Investing.com Canada
Using portfolio simulators with Biogen Inc. included2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Stifel Upgrades Biogen to Buy From Hold, Adjusts Price Target to $202 From $144 - MarketScreener
Exclusive: Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs - Reuters
Progressive Supranuclear Palsy Treatment Market Generated - openPR.com
Backtesting results for Biogen Inc. trading strategiesNew Guidance & Daily Price Action Insights - newser.com
Key metrics from Biogen Inc.’s quarterly data2025 Volume Leaders & Weekly Stock Performance Updates - newser.com
5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call - The Globe and Mail
Why Biogen Inc. stock is seen as undervaluedWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - fcp.pa.gov.br
When is the best time to exit Biogen Inc.Market Performance Recap & Low Risk Growth Stock Ideas - newser.com
Analyzing Biogen Inc. with multi timeframe chartsMarket Trend Report & Growth Focused Entry Reports - newser.com
Institutional scanner results for Biogen Inc.July 2025 Final Week & Weekly Top Performers Watchlists - newser.com
How to escape a deep drawdown in Biogen Inc.July 2025 Action & Community Consensus Stock Picks - newser.com
Will Biogen Inc. (IDP) stock benefit from commodity supercycleDay Trade & Weekly Market Pulse Updates - newser.com
Is Biogen Inc. stock a top momentum playJuly 2025 News Drivers & Real-Time Buy Signal Alerts - newser.com
How Biogen Inc. (IDP) stock behaves in tightening cyclesLong Setup & Detailed Earnings Play Alerts - newser.com
Biogen Fights To Defend MS Franchise Amid Generic Erosion And Biosimilar Threats - Citeline News & Insights
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
$185 million, proven team lead startup Braveheart Bio's toward late-stage heart drug trial - The Business Journals
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Should you wait for a breakout in Biogen Inc.Trade Analysis Summary & Low Risk Entry Point Tips - newser.com
Retirement Systems of Alabama Cuts Holdings in Biogen Inc. $BIIB - MarketBeat
Will Biogen Inc. (IDP) stock benefit from sector leadership2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Central Nervous System Disorders Therapeutics Market to Expand - openPR.com
Volatility clustering patterns for Biogen Inc.Weekly Market Summary & Stock Market Timing Techniques - newser.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Stoke Therapeutics Q3 revenue beats estimates on Acadia, Biogen agreements - MarketScreener
[Form 4] BIOGEN INC. Insider Trading Activity - Stock Titan
Biogen to Participate in Upcoming Investor Conferences - Biogen
Bank of America Securities Sticks to Their Hold Rating for Biogen (BIIB) - The Globe and Mail
Biogen’s yearslong lupus R&D journey could soon pay off - PharmaVoice
Sanford C. Bernstein Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Chart based exit strategy for Biogen Inc.Trade Volume Summary & Growth Focused Investment Plans - newser.com
Recombinant DNA Technology Market Surges with Breakthrough - openPR.com
Biogen Inc. $BIIB Shares Sold by iA Global Asset Management Inc. - MarketBeat
Biogen to present felzartamab data at Kidney Week 2025 By Investing.com - Investing.com Nigeria
Bernstein Maintains Biogen (BIIB) Market Perform Recommendation - Nasdaq
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):